We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProMetic Receives $4.6 Million Purchase Order from Octapharma
News

ProMetic Receives $4.6 Million Purchase Order from Octapharma

ProMetic Receives $4.6 Million Purchase Order from Octapharma
News

ProMetic Receives $4.6 Million Purchase Order from Octapharma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ProMetic Receives $4.6 Million Purchase Order from Octapharma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProMetic Life Sciences Inc. has announced that it has received a $4.6 million purchase order under its ongoing supply agreement with Octapharma, a leading, Swiss based, independent global plasma fractionation company that specializes in human proteins.

Shipments to Octapharma in relation to this order are expected to exceed $2.0 million during the second half of 2012.

This latest order relates to the purchase of PrioClear™, a proprietary prion capture resin incorporated into Octapharma's manufacturing process for its solvent/detergent treated plasma product, Octaplas™LG.

Octaplas™LG is currently approved for marketing in several European countries and the object of ongoing procedures for its regulatory approval for the North American market.

"This larger than originally anticipated purchase order from Octapharma for the second half of 2012 demonstrates the industry's growing demand for safer and differentiating plasma derived products", said Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc.

Laurin continued, "We are pleased to see our enabling technologies successfully demonstrating their market potential by way of deliveries for commercial applications at industrial scales", added Mr. Laurin.

Advertisement